Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Persistent Global Health Threat

Soligenix Inc. is progressing its CiVax COVID-19 vaccine candidate as global health data continues to highlight the persistent threat of the virus. Recent World Health Organization statistics reveal that between January 6 and February 2, 2025, over 147,000 new COVID-19 cases were reported worldwide, representing a 16% decrease from the previous period.

Despite the declining case numbers, the pandemic remains a significant concern. During the same timeframe, approximately 4,500 new COVID-19 deaths were reported, marking a 28% increase in mortality. This trend underscores the critical need for effective protective measures and treatments.

The company's CiVax vaccine candidate addresses this ongoing challenge through its proprietary, heat-stable design. Preclinical studies have demonstrated the vaccine's potential to induce rapid and broad protection against multiple COVID-19 variants, offering a promising approach to mitigating the virus's continued global impact.

While the Centers for Disease Control and Prevention reports that acute respiratory illness levels remain low in the United States as of April 11, 2025, the virus continues to circulate, highlighting the importance of continued vaccine research and development.